Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014–2019
| Autor: | Lynn M Neilson, Chronis Manolis, Kiraat D. Munshi, Chester B. Good, Samuel K Peasah, Elizabeth C S Swart, Yan Huang, Rochelle Henderson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Research design medicine.medical_specialty medicine.medical_treatment Pharmacy Type 2 diabetes Medicare Drug Costs Internal medicine medicine Humans Hypoglycemic Agents Insulin Medical prescription Aged Retrospective Studies Medicaid business.industry Public Health Environmental and Occupational Health Middle Aged Insurance Pharmaceutical Services medicine.disease United States Administrative claims Metformin Cross-Sectional Studies Diabetes Mellitus Type 2 Female Health Expenditures business medicine.drug |
| Zdroj: | Medical Care. 59:789-794 |
| ISSN: | 0025-7079 |
| DOI: | 10.1097/mlr.0000000000001597 |
| Popis: | OBJECTIVE The objective of this study was to describe national changes in utilization and associated costs of antidiabetic medications in the United States from 2014 to 2019, across different drug classes and insurance plans. RESEARCH DESIGN AND METHODS This retrospective, cross-sectional study examined administrative claims from a large national pharmacy benefits manager from January 1, 2014, to December 31, 2019. Patients aged 18 years and above enrolled in commercial, Medicare, or Medicaid health plans who filled ≥1 prescription claim for an antidiabetic medication(s) during the 6-year period were included. Utilization was examined as the total number of 30-day adjusted prescription fills per user per month (PUPM). Gross costs were calculated as the sum of plan costs (net of rebates) and member out-of-pocket costs. Differences in mean utilization and costs PUPM between 2014 and 2019 for each medication class were calculated. RESULTS The final analytic sample increased from 745,290 patients in 2014 to 1,596,006 in 2019. Antidiabetic medication utilization increased by 8.8% from 2014 to 2019, driven by increases in sodium-glucose cotransporter 2 inhibitor (48.7%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|